deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02363322

Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Conditions Ebola Virus Infection
Interventions A/Current Standard of Care Alone B/Current Standard of Care Plus ZMapp
Updated 14 times since 2017 Last updated: May 23, 2019 Started: Mar 13, 2015 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Ebola Virus Infection and is currently completed. Institut National de la Santé Et de la Recherche Médicale, France leads this study, which shows 14 recorded versions since 2015 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jun 2019 · 11 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Jan 2021 · 18 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Nov 2023 · 23 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Nov 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Dec 2021 — Nov 2023 [monthly]

    Completed PHASE1_PHASE2

▶ Show 9 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Jul 2019 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

    Status: Suspended → Completed

  3. Jun 2019 — Jul 2019 [monthly]

    Suspended PHASE1_PHASE2

  4. Jul 2018 — Jun 2019 [monthly]

    Suspended PHASE1_PHASE2

    Status: Active Not Recruiting → Suspended

  5. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Feb 2018 — May 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Feb 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institut National de la Santé Et de la Recherche Médicale, France
  • Ministry of Health and Sanitation, Sierra Leone
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • The Ministry of Health and Public Hygiene, Guinea
  • The Ministry of Health and Social Welfare, Liberia
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bethesda, United States , Forécariah, Guinea , Freetown, Sierra Leone , Goderich, Sierra Leone , Hastings, Sierra Leone , Jui, Sierra Leone , Kambia, Sierra Leone , Monrovia, Liberia , Paynesville, Liberia , Port Loko, Sierra Leone and 1 more location